Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer

Dino Amadori, Giovanni Luca Frassineti, Wainer Zoli, Carlo Milandri, Patrizia Serra, Amelia Tienghi, Alberto Ravaioli, Alfonso Gentile, Ernesto Salzano

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Based on preclinical data, we designed a phase I/II clinical trial to determine the efficacy and toxicity of doxorubicin followed by paclitaxel in the treatment of advanced breast cancer (either untreated or relapsed after adjuvant therapy). In the phase I dose-finding study, 19 enrolled patients received bolus doxorubicin (50 mg/m2) and, after a 16-hour interval, a three-hour infusion of paclitaxel in escalating doses from 130 to 250 mg/m2, increased by 30-mg/m2 increments for each dose-level group. The first dose level group (paclitaxel 130 mg/m2) included three patients. The other dose level groups included four patients. Treatment was repeated every three weeks for a maximum of eight cycles. The paclitaxel dose was escalated to 250 mg/m2 without reaching the maximum tolerated dose. In the 128 cycles assessable for toxicity, there were no relevant clinical signs or symptoms of cardiotoxicity. This absence of significant cardiotoxicity required confirmation in a phase II trial. Since a maximum tolerated dose of paclitaxel had not been reached during the first study and an increasing risk of neutropenia and peripheral neurotoxicity was feared if doses continued to escalate, a phase II confirmatory study was begun to evaluate treatment with fixed doses of doxorubicin (50 mg/m2) and paclitaxel (220 mg/m2), using the same schedule and interval as in phase I. The 13 patients enrolled in phase II received a total of 95 cycles of therapy; in 10 cycles (three patients) dose reductions were necessary because of toxicity. However, no significant clinical cardiotoxicity was observed in 12 of the 13 patients. One patient experienced an asymptomatic, transient decrease in left ventricular ejection fraction at a cumulative doxorubicin dose of 400 mg/m2. Overall clinical responses included 10 complete remissions (31.3%) and 15 partial remissions (46.9%) for an objective response rate of 78.1%. At 16 months' median follow- up, the median time to progression for all patients is nine months. The high response rate obtained in the phase I/II studies and, in particular, the absence of significant cardiotoxicity require confirmation in further clinical trials. To date, two confirmatory phase II trials are ongoing in our institutions.

Original languageEnglish
Pages (from-to)30-33
Number of pages4
JournalOncology
Volume11
Issue number4 SUPPL. 3
Publication statusPublished - 1997

Fingerprint

Paclitaxel
Doxorubicin
Breast Neoplasms
Maximum Tolerated Dose
Therapeutics
Phase II Clinical Trials
Clinical Trials, Phase I
Neutropenia
Stroke Volume
Signs and Symptoms
Appointments and Schedules
Clinical Trials
Cardiotoxicity

ASJC Scopus subject areas

  • Oncology

Cite this

Amadori, D., Frassineti, G. L., Zoli, W., Milandri, C., Serra, P., Tienghi, A., ... Salzano, E. (1997). Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer. Oncology, 11(4 SUPPL. 3), 30-33.

Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer. / Amadori, Dino; Frassineti, Giovanni Luca; Zoli, Wainer; Milandri, Carlo; Serra, Patrizia; Tienghi, Amelia; Ravaioli, Alberto; Gentile, Alfonso; Salzano, Ernesto.

In: Oncology, Vol. 11, No. 4 SUPPL. 3, 1997, p. 30-33.

Research output: Contribution to journalArticle

Amadori, D, Frassineti, GL, Zoli, W, Milandri, C, Serra, P, Tienghi, A, Ravaioli, A, Gentile, A & Salzano, E 1997, 'Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer', Oncology, vol. 11, no. 4 SUPPL. 3, pp. 30-33.
Amadori, Dino ; Frassineti, Giovanni Luca ; Zoli, Wainer ; Milandri, Carlo ; Serra, Patrizia ; Tienghi, Amelia ; Ravaioli, Alberto ; Gentile, Alfonso ; Salzano, Ernesto. / Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer. In: Oncology. 1997 ; Vol. 11, No. 4 SUPPL. 3. pp. 30-33.
@article{539aac2e7d374b3392b5f4810f820b8c,
title = "Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer",
abstract = "Based on preclinical data, we designed a phase I/II clinical trial to determine the efficacy and toxicity of doxorubicin followed by paclitaxel in the treatment of advanced breast cancer (either untreated or relapsed after adjuvant therapy). In the phase I dose-finding study, 19 enrolled patients received bolus doxorubicin (50 mg/m2) and, after a 16-hour interval, a three-hour infusion of paclitaxel in escalating doses from 130 to 250 mg/m2, increased by 30-mg/m2 increments for each dose-level group. The first dose level group (paclitaxel 130 mg/m2) included three patients. The other dose level groups included four patients. Treatment was repeated every three weeks for a maximum of eight cycles. The paclitaxel dose was escalated to 250 mg/m2 without reaching the maximum tolerated dose. In the 128 cycles assessable for toxicity, there were no relevant clinical signs or symptoms of cardiotoxicity. This absence of significant cardiotoxicity required confirmation in a phase II trial. Since a maximum tolerated dose of paclitaxel had not been reached during the first study and an increasing risk of neutropenia and peripheral neurotoxicity was feared if doses continued to escalate, a phase II confirmatory study was begun to evaluate treatment with fixed doses of doxorubicin (50 mg/m2) and paclitaxel (220 mg/m2), using the same schedule and interval as in phase I. The 13 patients enrolled in phase II received a total of 95 cycles of therapy; in 10 cycles (three patients) dose reductions were necessary because of toxicity. However, no significant clinical cardiotoxicity was observed in 12 of the 13 patients. One patient experienced an asymptomatic, transient decrease in left ventricular ejection fraction at a cumulative doxorubicin dose of 400 mg/m2. Overall clinical responses included 10 complete remissions (31.3{\%}) and 15 partial remissions (46.9{\%}) for an objective response rate of 78.1{\%}. At 16 months' median follow- up, the median time to progression for all patients is nine months. The high response rate obtained in the phase I/II studies and, in particular, the absence of significant cardiotoxicity require confirmation in further clinical trials. To date, two confirmatory phase II trials are ongoing in our institutions.",
author = "Dino Amadori and Frassineti, {Giovanni Luca} and Wainer Zoli and Carlo Milandri and Patrizia Serra and Amelia Tienghi and Alberto Ravaioli and Alfonso Gentile and Ernesto Salzano",
year = "1997",
language = "English",
volume = "11",
pages = "30--33",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4 SUPPL. 3",

}

TY - JOUR

T1 - Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer

AU - Amadori, Dino

AU - Frassineti, Giovanni Luca

AU - Zoli, Wainer

AU - Milandri, Carlo

AU - Serra, Patrizia

AU - Tienghi, Amelia

AU - Ravaioli, Alberto

AU - Gentile, Alfonso

AU - Salzano, Ernesto

PY - 1997

Y1 - 1997

N2 - Based on preclinical data, we designed a phase I/II clinical trial to determine the efficacy and toxicity of doxorubicin followed by paclitaxel in the treatment of advanced breast cancer (either untreated or relapsed after adjuvant therapy). In the phase I dose-finding study, 19 enrolled patients received bolus doxorubicin (50 mg/m2) and, after a 16-hour interval, a three-hour infusion of paclitaxel in escalating doses from 130 to 250 mg/m2, increased by 30-mg/m2 increments for each dose-level group. The first dose level group (paclitaxel 130 mg/m2) included three patients. The other dose level groups included four patients. Treatment was repeated every three weeks for a maximum of eight cycles. The paclitaxel dose was escalated to 250 mg/m2 without reaching the maximum tolerated dose. In the 128 cycles assessable for toxicity, there were no relevant clinical signs or symptoms of cardiotoxicity. This absence of significant cardiotoxicity required confirmation in a phase II trial. Since a maximum tolerated dose of paclitaxel had not been reached during the first study and an increasing risk of neutropenia and peripheral neurotoxicity was feared if doses continued to escalate, a phase II confirmatory study was begun to evaluate treatment with fixed doses of doxorubicin (50 mg/m2) and paclitaxel (220 mg/m2), using the same schedule and interval as in phase I. The 13 patients enrolled in phase II received a total of 95 cycles of therapy; in 10 cycles (three patients) dose reductions were necessary because of toxicity. However, no significant clinical cardiotoxicity was observed in 12 of the 13 patients. One patient experienced an asymptomatic, transient decrease in left ventricular ejection fraction at a cumulative doxorubicin dose of 400 mg/m2. Overall clinical responses included 10 complete remissions (31.3%) and 15 partial remissions (46.9%) for an objective response rate of 78.1%. At 16 months' median follow- up, the median time to progression for all patients is nine months. The high response rate obtained in the phase I/II studies and, in particular, the absence of significant cardiotoxicity require confirmation in further clinical trials. To date, two confirmatory phase II trials are ongoing in our institutions.

AB - Based on preclinical data, we designed a phase I/II clinical trial to determine the efficacy and toxicity of doxorubicin followed by paclitaxel in the treatment of advanced breast cancer (either untreated or relapsed after adjuvant therapy). In the phase I dose-finding study, 19 enrolled patients received bolus doxorubicin (50 mg/m2) and, after a 16-hour interval, a three-hour infusion of paclitaxel in escalating doses from 130 to 250 mg/m2, increased by 30-mg/m2 increments for each dose-level group. The first dose level group (paclitaxel 130 mg/m2) included three patients. The other dose level groups included four patients. Treatment was repeated every three weeks for a maximum of eight cycles. The paclitaxel dose was escalated to 250 mg/m2 without reaching the maximum tolerated dose. In the 128 cycles assessable for toxicity, there were no relevant clinical signs or symptoms of cardiotoxicity. This absence of significant cardiotoxicity required confirmation in a phase II trial. Since a maximum tolerated dose of paclitaxel had not been reached during the first study and an increasing risk of neutropenia and peripheral neurotoxicity was feared if doses continued to escalate, a phase II confirmatory study was begun to evaluate treatment with fixed doses of doxorubicin (50 mg/m2) and paclitaxel (220 mg/m2), using the same schedule and interval as in phase I. The 13 patients enrolled in phase II received a total of 95 cycles of therapy; in 10 cycles (three patients) dose reductions were necessary because of toxicity. However, no significant clinical cardiotoxicity was observed in 12 of the 13 patients. One patient experienced an asymptomatic, transient decrease in left ventricular ejection fraction at a cumulative doxorubicin dose of 400 mg/m2. Overall clinical responses included 10 complete remissions (31.3%) and 15 partial remissions (46.9%) for an objective response rate of 78.1%. At 16 months' median follow- up, the median time to progression for all patients is nine months. The high response rate obtained in the phase I/II studies and, in particular, the absence of significant cardiotoxicity require confirmation in further clinical trials. To date, two confirmatory phase II trials are ongoing in our institutions.

UR - http://www.scopus.com/inward/record.url?scp=0030819392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030819392&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 30

EP - 33

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4 SUPPL. 3

ER -